MGNX up +5.85% percent right now. $MGNX High is at
Post# of 74552
Posted On: 11/10/2014 2:16:51 PM
MGNX up +5.85% percent right now. $MGNX High is at 21.14 and the Low 19.85 with current volume of 63,127.
Recent News posted below.
MGNX Macrogenics Inc Recent Headline News
What To Watch For: November 10-14
TipRanks - Seeking Alpha - 2 hrs 40 mins ago
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 41.32 (+1.88), DHI: 23.55 (+0.42), MGNX: 21.14 (+1.30), KSS: 56.74 (-0.48), HK: 3.21 (-0.03), SEAS: 18.49 (+0.10), DDD: 36.44 (+1.97), SBH: 28.74 (-0.36), WMT: 79.84 (+1.07), M: 59.45 (-0.43), HP: 86.28 (-0.42), NTAP: 42.28 (-0.02), ENR: 125.02 (+1.52), MACK: 8.65 (-0.05), W: 26.70 (+0.69), FOSL: 103.21 (+0.20), AMAT: 22.62 (+0.19), JCP: 7.37 (-0.45), JWN: 72.47 (-0.96), PE: 16.45 (+0.03), DF: 16.35 (+1.93), VIAB: 70.11 (-0.52), CSCO: 25.17 (-0.16), ATW: 37.68 (-0.53)
MacroGenics Announces Pre-clinical Data to be Presented at ASH 2014 Annual Meeting
GlobeNewswire - Thu Nov 06, 3:21PM CST
ROCKVILLE, Md., November 6, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that pre-clinical data on MGD011, a humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART(R)) protein, will be highlighted in a poster presentation at the 56 Annual Meeting of the American Society of Hematology (ASH), to be held December 6-9, 2014 in San Francisco, CA.
MGNX: 21.14 (+1.30)
MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium
GlobeNewswire - Thu Oct 30, 4:00PM CDT
MacroGenics to Present Pre-Clinical Data on MGD006 at 26 EORTC-NCI-AACR Symposium
MGNX: 21.14 (+1.30)
MacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Oct 28, 4:00PM CDT
The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
MGNX: 21.14 (+1.30)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 21.14 (+1.30), IMMU: 3.64 (+0.03), ONCY: 0.82 (+0.12), ARQL: 1.15 (+0.09), AMGN: 162.19 (+1.94), LLY: 68.17 (+1.57), BMY: 58.47 (+0.15), GILD: 107.31 (+0.86), SNY: 46.26 (+0.57), REGN: 382.50 (+4.66)
MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
GlobeNewswire - Mon Sep 29, 6:00PM CDT
ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates. These four research programs are in addition to MGD010, which was the subject of a prior agreement announced in May 2014. Each of these product candidates will be directed against jointly selected pairs of molecular targets and incorporate MacroGenics' Dual-Affinity Re-Targeting (DART(R)) proprietary platform.
MGNX: 21.14 (+1.30)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 21.14 (+1.30), CMRX: 31.20 (+0.45), CVM: 0.64 (+0.04), SIGA: 1.63 (+0.07)
Stock Futures In Positive Mood; Bon Ton Stores Skid Lower
at Investor's Business Daily - Thu Aug 21, 8:09AM CDT
Stock futures stuck to their early gains ahead of Thursday's open, as Europe's markets traded higher and weekly jobless claims data was positive. Dow futures rose 31. 9 points above fair market value. Nasdaq 100 futures notched up 3.6 points and S&P...
MGNX: 21.14 (+1.30), DLTR: 61.81 (+0.25), BONT: 8.34 (-0.32), KIN: 8.90 (-0.10)
MacroGenics to Present at the Wedbush 2014 Life Sciences Management Access Conference
GlobeNewswire - Wed Aug 06, 3:51PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Wedbush 2014 Life Sciences Management Access Conference. The presentation will take place Wednesday, August 13, 2014, at 1:55 p.m. Eastern Time in New York, NY.
MGNX: 21.14 (+1.30)
MacroGenics Provides Update on Corporate Progress and Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 3:09PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate progress update and reported financial results for the quarter ended June 30, 2014.
MGNX: 21.14 (+1.30)
MacroGenics Announces Date of Second Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Jul 29, 3:01PM CDT
MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014, the Company will release its financial results for the quarter ended June 30, 2014. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Tuesday, August 5, 2014 at 4:30 pm (EDT). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 79551617.
MGNX: 21.14 (+1.30)
MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients
GlobeNewswire - Thu Jul 24, 4:17PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that its investigational new drug (IND) for MGD007 has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with the Phase 1 human clinical trial for this drug candidate. MGD007 is a Dual-Affinity Re-Targeting (DART(R)) protein being developed for the treatment of colorectal cancer. MacroGenics will receive a $5 million milestone payment from Servier, France's largest privately-held pharmaceutical company, triggered by the IND clearance.
MGNX: 21.14 (+1.30)
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
MGNX: 21.14 (+1.30), BIIB: 325.55 (+4.80), PCYC: 133.73 (+0.24), OMED: 20.22 (+0.03), HA: 18.44 (+0.07), HWAY: 15.04 (-0.10), QDEL: 27.72 (-0.15), OSTK: 24.07 (-0.13), NVEC: 74.11 (+0.19), DWCH: 11.04 (+0.34), ISRG: 506.50 (+6.48), VDSI: 27.85 (+1.22), LOGI: 14.12 (+0.29), NEOG: 43.55 (+0.54), VASC: 29.86 (-0.18), IMCB: 20.00 (+0.31), SODA: 21.37 (-0.63), EGHT: 7.91 (+0.27)
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
MGNX: 21.14 (+1.30), ADXS: 2.88 (+0.13), IMMU: 3.64 (+0.03), CERU: 5.80 (+0.29), AMGN: 162.18 (+1.93), BMY: 58.47 (+0.15), CTIC: 2.10 (-0.03), GSK: 45.11 (+0.20), OMER: 17.18 (-0.19), MACK: 8.62 (-0.08), SNTA: 3.10 (-0.04), GILD: 107.31 (+0.86), KITE: 43.30 (-2.69), NVS: 92.33 (+0.57)
MacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia
GlobeNewswire - Thu Jun 19, 5:59AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune disease, today announced that a first patient received drug in a Phase 1 study of MGD006 in relapsed or refractory acute myeloid leukemia (AML). MGD006 is a humanized, Dual-Affinity Re-Targeting (DART(R)) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate.
MGNX: 21.14 (+1.30)
CMC Biologics and MacroGenics Enter into Process Validation and Clinical Manufacturing Agreement for Commercialization of Next-Generation Oncology Product Candidate
PR Newswire - Tue Jun 17, 6:00AM CDT
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into a Master Services Agreement for process validation activities and clinical manufacturing of another of MacroGenics' oncology product candidates.
MGNX: 21.14 (+1.30)
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
MGNX: 21.14 (+1.30), CMRX: 31.19 (+0.44), CVM: 0.64 (+0.04), SIGA: 1.63 (+0.07)
Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free.
MGNX: 21.14 (+1.30), ALNY: 98.55 (+2.71), CLDX: 14.48 (+1.06), SPPI: 7.43 (+0.10), KERX: 16.43 (-0.30)
MacroGenics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 7:01AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13 Annual Needham Healthcare Conference. The presentation will take place Tuesday, April 8, 2014, at 5:00 p.m. Eastern Time in New York.
MGNX: 21.14 (+1.30)
MacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting
GlobeNewswire - Mon Mar 31, 7:29AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on its colorectal cancer product candidate, MGD007, will be presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The poster, titled "Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer," will be presented Sunday, April 6, 2014, from 1:00-5:00pm PT in Hall A-E, poster section 28, poster number 26.
MGNX: 21.14 (+1.30)
Recent News posted below.
MGNX Macrogenics Inc Recent Headline News
What To Watch For: November 10-14
TipRanks - Seeking Alpha - 2 hrs 40 mins ago
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 41.32 (+1.88), DHI: 23.55 (+0.42), MGNX: 21.14 (+1.30), KSS: 56.74 (-0.48), HK: 3.21 (-0.03), SEAS: 18.49 (+0.10), DDD: 36.44 (+1.97), SBH: 28.74 (-0.36), WMT: 79.84 (+1.07), M: 59.45 (-0.43), HP: 86.28 (-0.42), NTAP: 42.28 (-0.02), ENR: 125.02 (+1.52), MACK: 8.65 (-0.05), W: 26.70 (+0.69), FOSL: 103.21 (+0.20), AMAT: 22.62 (+0.19), JCP: 7.37 (-0.45), JWN: 72.47 (-0.96), PE: 16.45 (+0.03), DF: 16.35 (+1.93), VIAB: 70.11 (-0.52), CSCO: 25.17 (-0.16), ATW: 37.68 (-0.53)
MacroGenics Announces Pre-clinical Data to be Presented at ASH 2014 Annual Meeting
GlobeNewswire - Thu Nov 06, 3:21PM CST
ROCKVILLE, Md., November 6, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that pre-clinical data on MGD011, a humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART(R)) protein, will be highlighted in a poster presentation at the 56 Annual Meeting of the American Society of Hematology (ASH), to be held December 6-9, 2014 in San Francisco, CA.
MGNX: 21.14 (+1.30)
MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium
GlobeNewswire - Thu Oct 30, 4:00PM CDT
MacroGenics to Present Pre-Clinical Data on MGD006 at 26 EORTC-NCI-AACR Symposium
MGNX: 21.14 (+1.30)
MacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Oct 28, 4:00PM CDT
The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
MGNX: 21.14 (+1.30)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 21.14 (+1.30), IMMU: 3.64 (+0.03), ONCY: 0.82 (+0.12), ARQL: 1.15 (+0.09), AMGN: 162.19 (+1.94), LLY: 68.17 (+1.57), BMY: 58.47 (+0.15), GILD: 107.31 (+0.86), SNY: 46.26 (+0.57), REGN: 382.50 (+4.66)
MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
GlobeNewswire - Mon Sep 29, 6:00PM CDT
ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates. These four research programs are in addition to MGD010, which was the subject of a prior agreement announced in May 2014. Each of these product candidates will be directed against jointly selected pairs of molecular targets and incorporate MacroGenics' Dual-Affinity Re-Targeting (DART(R)) proprietary platform.
MGNX: 21.14 (+1.30)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 21.14 (+1.30), CMRX: 31.20 (+0.45), CVM: 0.64 (+0.04), SIGA: 1.63 (+0.07)
Stock Futures In Positive Mood; Bon Ton Stores Skid Lower
at Investor's Business Daily - Thu Aug 21, 8:09AM CDT
Stock futures stuck to their early gains ahead of Thursday's open, as Europe's markets traded higher and weekly jobless claims data was positive. Dow futures rose 31. 9 points above fair market value. Nasdaq 100 futures notched up 3.6 points and S&P...
MGNX: 21.14 (+1.30), DLTR: 61.81 (+0.25), BONT: 8.34 (-0.32), KIN: 8.90 (-0.10)
MacroGenics to Present at the Wedbush 2014 Life Sciences Management Access Conference
GlobeNewswire - Wed Aug 06, 3:51PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig, M.D., Ph.D., President and CEO will present at the Wedbush 2014 Life Sciences Management Access Conference. The presentation will take place Wednesday, August 13, 2014, at 1:55 p.m. Eastern Time in New York, NY.
MGNX: 21.14 (+1.30)
MacroGenics Provides Update on Corporate Progress and Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 3:09PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided a corporate progress update and reported financial results for the quarter ended June 30, 2014.
MGNX: 21.14 (+1.30)
MacroGenics Announces Date of Second Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Jul 29, 3:01PM CDT
MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014, the Company will release its financial results for the quarter ended June 30, 2014. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Tuesday, August 5, 2014 at 4:30 pm (EDT). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 79551617.
MGNX: 21.14 (+1.30)
MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients
GlobeNewswire - Thu Jul 24, 4:17PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that its investigational new drug (IND) for MGD007 has been cleared by the U.S. Food and Drug Administration (FDA) to proceed with the Phase 1 human clinical trial for this drug candidate. MGD007 is a Dual-Affinity Re-Targeting (DART(R)) protein being developed for the treatment of colorectal cancer. MacroGenics will receive a $5 million milestone payment from Servier, France's largest privately-held pharmaceutical company, triggered by the IND clearance.
MGNX: 21.14 (+1.30)
Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 12:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
MGNX: 21.14 (+1.30), BIIB: 325.55 (+4.80), PCYC: 133.73 (+0.24), OMED: 20.22 (+0.03), HA: 18.44 (+0.07), HWAY: 15.04 (-0.10), QDEL: 27.72 (-0.15), OSTK: 24.07 (-0.13), NVEC: 74.11 (+0.19), DWCH: 11.04 (+0.34), ISRG: 506.50 (+6.48), VDSI: 27.85 (+1.22), LOGI: 14.12 (+0.29), NEOG: 43.55 (+0.54), VASC: 29.86 (-0.18), IMCB: 20.00 (+0.31), SODA: 21.37 (-0.63), EGHT: 7.91 (+0.27)
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
MGNX: 21.14 (+1.30), ADXS: 2.88 (+0.13), IMMU: 3.64 (+0.03), CERU: 5.80 (+0.29), AMGN: 162.18 (+1.93), BMY: 58.47 (+0.15), CTIC: 2.10 (-0.03), GSK: 45.11 (+0.20), OMER: 17.18 (-0.19), MACK: 8.62 (-0.08), SNTA: 3.10 (-0.04), GILD: 107.31 (+0.86), KITE: 43.30 (-2.69), NVS: 92.33 (+0.57)
MacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia
GlobeNewswire - Thu Jun 19, 5:59AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune disease, today announced that a first patient received drug in a Phase 1 study of MGD006 in relapsed or refractory acute myeloid leukemia (AML). MGD006 is a humanized, Dual-Affinity Re-Targeting (DART(R)) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate.
MGNX: 21.14 (+1.30)
CMC Biologics and MacroGenics Enter into Process Validation and Clinical Manufacturing Agreement for Commercialization of Next-Generation Oncology Product Candidate
PR Newswire - Tue Jun 17, 6:00AM CDT
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into a Master Services Agreement for process validation activities and clinical manufacturing of another of MacroGenics' oncology product candidates.
MGNX: 21.14 (+1.30)
Smallpox - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ndtlnz/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smallpox - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Mentioned: - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - GeoVax Labs, Inc. - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - NanoBio Corporation - Conkwest, Inc. For more information visit http://www.researchandmarkets.com/research/ndtlnz/smallpox
MGNX: 21.14 (+1.30), CMRX: 31.19 (+0.44), CVM: 0.64 (+0.04), SIGA: 1.63 (+0.07)
Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free.
MGNX: 21.14 (+1.30), ALNY: 98.55 (+2.71), CLDX: 14.48 (+1.06), SPPI: 7.43 (+0.10), KERX: 16.43 (-0.30)
MacroGenics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 7:01AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13 Annual Needham Healthcare Conference. The presentation will take place Tuesday, April 8, 2014, at 5:00 p.m. Eastern Time in New York.
MGNX: 21.14 (+1.30)
MacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting
GlobeNewswire - Mon Mar 31, 7:29AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on its colorectal cancer product candidate, MGD007, will be presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The poster, titled "Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer," will be presented Sunday, April 6, 2014, from 1:00-5:00pm PT in Hall A-E, poster section 28, poster number 26.
MGNX: 21.14 (+1.30)
(0)
(0)